Realtime | Geld | Brief | Zeit |
---|---|---|---|
24,350 | 25,400 | 24.09. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | BASTIDE: Groupe Bastide completes the sale of Baywater Healthcare to Sapio Group | 203 | Actusnews Wire | Caissargues, September 24, 2025
In line with the timetable set out in its 30 June 2025 communication announcing the agreement to sell Baywater Healthcare, a leading player in the UK respiratory... ► Artikel lesen | |
04.09. | BASTIDE: 2024-2025 revenue target met // 2024-2025 revenue from continuing operations: EUR 491 million, up 8% ( EUR 561 million, excluding impact of disposals) | 312 | Actusnews Wire | Caissargues, September 4, 2025
Groupe Bastide has published its annual revenue for 2024-2025. In accordance with IFRS 5, reported revenue relates exclusively to continuing operations, and no... ► Artikel lesen | |
23.07. | La Bastide: A Taste Of Provence, One Hour From New York City | 2 | Forbes | ||
30.06. | BASTIDE: Bastide Groupe Sells Baywater Healthcare To Sapio Group | 526 | Actusnews Wire | Crewe, United Kingdom & Monza, Italy - 30th June 2025
Bastide le Confort Medical SA (hereinafter "Groupe Bastide") today announced that it has agreed to the sale of its subsidiary Baywater Healthcare... ► Artikel lesen | |
09.06. | BASTIDE: Disposal of CICADUM and MEDSOFT | 453 | Actusnews Wire | Caissargues, June 9, 2025
Bastide Groupe announced today the disposal of its French subsidiaries, Cicadum, 51%-owned, (signing subject to financing condition precedent) and Medsoft, 100%-owned... ► Artikel lesen | |
05.06. | BASTIDE: Disposal of DORGE and DYNA MEDICAL in Belgium | 429 | Actusnews Wire | Caissargues, June 5, 2025
Bastide Groupe announced today the disposal of its Belgian subsidiaries, Dorge Medic, which specializes in the sale and rental of medical equipment and products for... ► Artikel lesen | |
BASTIDE LE CONFORT MEDICAL Aktie jetzt für 0€ handeln | |||||
04.06. | BASTIDE: Respiratory care therapy: Baywater wins London region tender and consolidates its leading position in the UK | 393 | Actusnews Wire | Caissargues, June 4, 2025
After being chosen one year ago by the National Health Service (NHS) to be the exclusive operator for respiratory care (oxygen therapy) in the East of England region... ► Artikel lesen | |
15.05. | BASTIDE: Continued strong organic growth in Q3 2024-2025 at +7.7%: Home healthcare services up 10.4% and recovery of Homecare activities confirmed / 2024-2025 targets confirmed | 416 | Actusnews Wire | Caissargues, May 15, 2025
In € millions
2023-2024
published
2023-2024*
Adjusted
2024-2025
published
Change
First-quarter revenue
127.9
122.7
133.8
+9.1%
Second-quarter... ► Artikel lesen | |
19.03. | BASTIDE: 2024-2025 half-year results / Recurring operating margin at 9.1%, up 80 bps / Operating FCF positive at EUR 9.4 million / Improvement in financial leverage / upward revision of recurring operating margin target to 9.1% | 535 | Actusnews Wire | Caissargues, March 19, 2025 - Groupe Bastide, a leading European provider of home healthcare services, published its 2024-2025 half-year results on December 31, 2024. Groupe Bastide's 2024-2025... ► Artikel lesen | |
13.02. | BASTIDE: Organic growth of 8.4% in first-half 2024 2025: Home healthcare services up 10.2% and Return to growth in the Homecare business / 2024-2025 targets confirmed | 410 | Actusnews Wire | Caissargues, February 13, 2025
In € millions
2023-2024
published
2023-2024*
Adjusted
2024-2025
published
Change
First-quarter revenue
127.9
122.7
133.8
+9.1%
Second-quarter... ► Artikel lesen | |
08.01. | BASTIDE obtains an extended license to operate in Canada in the Respiratory Care segment / Sale of French stomatherapy subsidiary CICA PLUS | 350 | Actusnews Wire | Caissargues, January 8, 2025 - Groupe Bastide, one of Europe's leading players in home healthcare services, announces its newly extended license to operate in the field of respiratory care in British... ► Artikel lesen | |
14.11.24 | BASTIDE: Highly dynamic organic growth in Q1 2024-25 at 9.0%: 10.9% growth in home healthcare services and rebound in the homecare business, up 6.0% / Disposal of Swiss commercial business finalized and 2024-2025 targets confirmed | 421 | Actusnews Wire | Caissargues, November 14, 2024 - Groupe Bastide, a leading European provider of home healthcare services, has published its revenue for first-quarter 2024-2025, ending September 30, 2024.
In... ► Artikel lesen | |
04.11.24 | BASTIDE: 2024-2025 financial calendar | 330 | Actusnews Wire | Caissargues, November 4, 2024
Events
Dates*
2024-2025 Q1 Revenue
Thursday November 14, 2024
2024-2025 H1 Revenue
Thursday February 13, 2025
2024-2025 H1 Results
Wednesday... ► Artikel lesen | |
23.10.24 | BASTIDE: 2023-2024 annual results: Solid growth in revenue and recurring operating margin of 8.5%, exceeding the target / improved profitability and a focus on reducing debt in 2024-25 | 350 | Actusnews Wire | Caissargues, October 23, 2024 - Groupe Bastide, leading European provider of home healthcare services, announces its earnings for the 2023-2024 financial year ended 30 June 2024. The full-year... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ANSELL | 18,300 | -2,66 % | ANSELL LIMITED: Change in substantial holding | ||
AMBEA | 11,880 | -0,50 % | Ambea AB: Ambea's interim report April - June 2025 | strong>Higher growth rate and earnings
CEO comments:
We reported a strong trend during the quarter, with clear growth in sales and earnings. A significant part of this growth was driven by Validia... ► Artikel lesen | |
GERRESHEIMER | 36,200 | -15,42 % | Aixtron, Evotec, Gerresheimer, HelloFresh, Redcare Pharmacy, TeamViewer - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
SIEMENS HEALTHINEERS | 46,430 | -1,38 % | Siemens Healthineers kooperiert für Robotersystem mit Stryker | DJ Siemens Healthineers kooperiert für Robotersystem mit Stryker
DOW JONES--Siemens Healthineers will ein Robotersystem für die Behandlung von Schlaganfällen und Aneurysmen gemeinsam mit dem US-Medizintechnologieunternehmen... ► Artikel lesen | |
FRESENIUS MEDICAL CARE | 44,120 | +0,62 % | FMC erhöht Beteiligung an Value-Based-Care-Geschäft | DJ FMC erhöht Beteiligung an Value-Based-Care-Geschäft
DOW JONES--Fresenius Medical Care (FMC) hat ihre Beteiligung am operativen Segment Value-Based-Care (VBC) erhöht und treibt damit nach eigenen... ► Artikel lesen | |
FRESENIUS | 46,770 | -0,60 % | DAX vor Fed-Entscheid stabilisiert: Commerzbank, Fresenius, Munich Re, Beiersdorf, Tesla im ... | Am Dienstag gab es am deutschen Aktienmarkt deutliche Gewinnmitnahmen. Der DAX ging am Ende mit einem Minus von 1,8 Prozent bei 23.329,24 Zählern aus dem Handel. Zum Start in den heutigen Mittwoch dürfte... ► Artikel lesen | |
CARL ZEISS MEDITEC | 45,720 | -0,48 % | CARL ZEISS MEDITEC AG: Hier zündet die nächste Kursrakete! | ||
UNITEDHEALTH | 300,35 | +2,04 % | HeraMED - Der nächste große KI-Durchbruch in der Frauengesundheit? | ||
CLEARPOINT NEURO | 19,250 | 0,00 % | ClearPoint Neuro, Inc.: ClearPoint Neuro Announces FDA Clearance Expanding Compatibility of the ClearPoint Prism Neuro Laser Therapy System with 1.5T MRI Scanners | SOLANA BEACH, CALIFORNIA / ACCESS Newswire / September 4, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation... ► Artikel lesen | |
HIMS & HERS HEALTH | 45,440 | -4,11 % | Hims & Hers: Zeit für den nächsten Kursschub? | Hims & Hers zeigt nach dem Test eines wichtigen Pivot-Tiefs Stärke. Könnte der hohe Short-Anteil der Aktie den nächsten Kursschub auslösen Den vollständigen Artikel lesen ... ► Artikel lesen | |
ALIGNMENT HEALTHCARE | 17,390 | +2,08 % | Alignment Healthcare USA, LLC: Aging in Place, Limited Access to Medical Care and Economic Insecurity Threaten U.S. Senior Health | ||
ECKERT & ZIEGLER | 18,090 | +0,56 % | EQS-News: Eckert & Ziegler SE: Eckert & Ziegler erhält Zulassung für GalliaPharm® in Japan | EQS-News: Eckert & Ziegler SE
/ Schlagwort(e): Zulassungsgenehmigung/Markteinführung
Eckert & Ziegler erhält Zulassung für GalliaPharm® in Japan
19.09.2025 / 12:00 CET/CEST
Für... ► Artikel lesen | |
GENEDX | 114,37 | 0,00 % | GeneDx beruft KI-Spezialisten Thomas Fuchs in den Vorstand und erweitert Gremium | ||
STRATEC | 29,850 | -2,61 % | Aktie von Stratec heute am Aktienmarkt gefragt (28,35 €) | Im Plus liegt zur Stunde die Stratec-Aktie . Die Aktie kostete zuletzt 28,35 Euro. An der deutschen Börse hat sich heute der Anteilsschein von Stratec zwischenzeitlich um 2,72 Prozent verteuert. Der... ► Artikel lesen | |
ESSILORLUXOTTICA | 269,40 | -1,54 % | RBC stuft EssilorLuxottica auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat die Einstufung für EssilorLuxottica auf "Outperform" mit einem Kursziel von 290 Euro belassen. Die erweiterte Angebotspalette an Datenbrillen... ► Artikel lesen |